A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity…
The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers continue…
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs…
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
